These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 22924510

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Spinal muscular atrophy: from gene to therapy.
    Wirth B, Brichta L, Hahnen E.
    Semin Pediatr Neurol; 2006 Jun; 13(2):121-31. PubMed ID: 17027862
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA).
    Wirth B.
    Hum Mutat; 2000 Jun; 15(3):228-37. PubMed ID: 10679938
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
    Thurmond J, Butchbach ME, Palomo M, Pease B, Rao M, Bedell L, Keyvan M, Pai G, Mishra R, Haraldsson M, Andresson T, Bragason G, Thosteinsdottir M, Bjornsson JM, Coovert DD, Burghes AH, Gurney ME, Singh J.
    J Med Chem; 2008 Feb 14; 51(3):449-69. PubMed ID: 18205293
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Molecular genetic basis of proximal spinal muscular atrophy and experience in its pharmaceutical treatment].
    Baranov VS, Kiselev AV, Vakharlovskiĭ VG, Zhelezniakova GIu, Komantsev VN, Malysheva OV, Glotov AS, Ivashchenko TE, Baranov AN.
    Genetika; 2008 Oct 14; 44(10):1325-37. PubMed ID: 19062530
    [Abstract] [Full Text] [Related]

  • 12. Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy.
    Rindt H, Buckley DM, Vale SM, Krogman M, Rose FF, Garcia ML, Lorson CL.
    Neuromuscul Disord; 2012 Mar 14; 22(3):277-85. PubMed ID: 22079083
    [Abstract] [Full Text] [Related]

  • 13. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS.
    Veldink JH, Kalmijn S, Van der Hout AH, Lemmink HH, Groeneveld GJ, Lummen C, Scheffer H, Wokke JH, Van den Berg LH.
    Neurology; 2005 Sep 27; 65(6):820-5. PubMed ID: 16093455
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Spinal muscular atrophy: from animal model to clinical trial.
    Zanoteli E, Maximino JR, Conti Reed U, Chadi G.
    Funct Neurol; 2010 Sep 27; 25(2):73-9. PubMed ID: 20923604
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Spinal muscular atrophy.
    Vitte J, Attali R, Warwar N, Gurt I, Melki J.
    Adv Exp Med Biol; 2009 Sep 27; 652():237-46. PubMed ID: 20225030
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.